Rheumatology Advisor

Bimekizumab Shows Consistent Long-Term Safety in PsA and axSpA

Bimekizumab demonstrated a consistent safety profile across patients with PsA or axSpA in an integrated safety analysis, with the drug showing long-term tolerability.
Morningstar

BIMZELX® (bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

ATLANTA, March 11, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® ...
The American Journal of Managed Care

Bimekizumab Shows Long-Term Efficacy in Nonradiographic AxSpA, Ankylosing Spondylitis

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). Bimekizumab is currently FDA approved ...
Dermatology Advisor

Bimekizumab Improves Patient-Reported Outcomes for Plaque PsO Through 3 Years

Bimekizumab is associated with significant improvements through 3 years across various patient-reported outcomes in those ...
The American Journal of Managed Care

Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD

Among the most striking findings, 86.1% of patients treated with bimekizumab were completely flare-free across the entire ...
FierceBiotech

UCB's bimekizumab blows J&J's Stelara away in phase 3, raising expectations for Cosentyx showdown

UCB has presented detailed phase 3 data on psoriasis prospect bimekizumab, raising expectations that it can deliver a telling blow to Novartis’ Cosentyx in an upcoming head-to-head study. Shares in ...
Dermatology Advisor

Bimekizumab Is Efficacious for Hidradenitis Suppurativa Across IHS4 Measures

Bimekizumab at different dosing intervals was associated with greater IHS4 improvements at week 48 than placebo in patients with HS.
Business Insider

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

BRUSSELS, Oct. 31, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients ...
Healio

Bimekizumab reduces disease severity among patients with hidradenitis suppurativa

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients treated with bimekizumab vs. placebo achieved the primary endpoint of HiSCR50.
Yahoo Finance

BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

Symptom relief sustained to three years: Improvements in the stringent endpoints HiSCR75, HiSCR90, and HiSCR100 at one year were sustained to three years in 81.2%, 64.3%, and 50.1% of patients, ...
Healio

Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rapid responses to bimekizumab were sustained over 52 ...
Yahoo Finance

BIMZELX® (bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

Primary endpoint showing superiority met: Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity, as measured by the stringent ACR50 endpoint, at ...